At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,257 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Plaque Psoriasis. Completed, enrolled 1,257 participants across 125 sites in 14 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesArgentina, Australia, Canada, Czechia, Germany, Hungary, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionNov 2016
Study CompletionAug 2017
TodayJul 2026
First PostedJul 31, 2015
Enrollment StartAug 1, 2015
Primary CompletionNov 1, 2016
Study CompletionAug 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.9 years ago
Interventions
Ixekizumabdrug
Administered SQ
Placebodrug
Administered SQ